The effects of Chinese proprietary medicine and vaccination on patients with COVID-19: a retrospective study in Macao.

The effects of Chinese proprietary medicine and vaccination on patients with COVID-19: a retrospective study in Macao.

Publication date: Jan 23, 2024

COVID-19 is continuing to ravage globally and has resulted in a huge health and financial burden. Chinese proprietary medicines, such as Lianhua Qingwen (LHQW) and Huoxiang Zhengqi (HXZQ) capsules, have been recommended for non-high-risk patients with COVID-19 in China. Based on this, we described the baseline information, using status of LHQW and HXZQ capsules and inoculation history of quarantined patients in the second half of 2022 in Macao. Additionally, we analyzed the underlying association among medicines administration, vaccination and COVID-19 indices, in order to explore novel clues for the regular control and prevention of local epidemic situation in the future. A total of 976 patients in Macao quarantine hotels from June to August 2022 were included in the present study, of which, 857 subjects were followed-up for prognosis evaluation. During quarantine, the baseline demographic information, including sex, age, BMI, occupation and personal habits were collected. Additionally, the inoculation history, medicine employment status and cycle threshold (Ct) values were also reported. We interviewed the patients for collection of their symptoms at the beginning and end of quarantine, as well as prognostic ones. Basic statistical description of baseline information, vaccination history and medication were displayed. Chi-squared test or with continuous correction test was employed for comparison of dichotomous data between two or multiple groups. Binary logistic regression was applied to reveal the correlation between potential risk factors and Ct values or prognosis symptoms. We also used Cox regression model to identify the effect of different types of vaccine products on Ct value altering rate. Patients who were female (52. 0%), engaged in service industry (31. 8%), from Macao native (65. 8%), never took physical exercises (33. 6%) and preferred irritated diet (59. 5%) enjoyed more dominant proportions. Over 80% of participants were inoculated and 74. 6% of them chose inactivated COVID-19 vaccine produced by China National Biotech Group (CNBG). Participants used LHQW capsules accounted for 92. 1% and the duration of medicating lasted for one to two weeks. All of the reported symptoms were significantly ameliorated after quarantine and the duration of quarantine was concentrated on 21 days. People with different age, sex, occupation and region had different choices of HXZQ administration and vaccination. Additionally, middle dose (4-5 boxes) of LHQW capsules exhibited evidently negative association with positive Ct values (adjusted, – 0. 037 +/- 0. 19, p = 0. 04). Two doses of CNBG and one dose of mRNA vaccine had obvious protective effect on reducing Ct positive rate (p = 0. 041). Meanwhile, symptoms after quarantine were significantly positive correlated with those in prognosis (adjusted, 1. 38 +/- 0. 18, p 

Concepts Keywords
21days Chinese proprietary medicine
August COVID-19
Biotech Huoxiang Zhengqi capsule
China Lianhua Qingwen capsule


Type Source Name
disease VO vaccination
disease MESH COVID-19
disease IDO history
disease VO vaccine
disease VO COVID-19 vaccine
disease VO dose

Original Article

(Visited 1 times, 1 visits today)